DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastrointestinal Stromal Tumor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Gastrointestinal Stromal Tumor Pipeline Report
- DelveInsight’s Gastrointestinal Stromal Tumor pipeline report depicts a robust space with 25+ active players working to develop 28+ pipeline therapies for Gastrointestinal Stromal Tumor treatment.
- The leading companies working in the Gastrointestinal Stromal Tumor Market include Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx Inc., Allarity Therapeutics, and others.
- Promising Gastrointestinal Stromal Tumor Pipeline Therapies in the various stages of development include DCC-2618, Ripretinib, Sunitinib, DS-6157a, and others.
- November 2023: Sumitomo Pharma America Inc. announced a study of Phase 2 clinical trials for BBI503. This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced gastrointestinal stromal tumor who have exhausted all currently approved standard anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no longer clinically benefiting from therapy due to disease progression, adverse events, or another discontinuation criterion.
- November 2023: Cogent Biosciences Inc. announced a study of Phase 3 clinical trials for CGT9486 plus sunitinib. This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being randomized in a 1:1 manner.
Request a sample and discover the recent advances in Gastrointestinal Stromal Tumor Treatment Drugs @ Gastrointestinal Stromal Tumor Pipeline Report
In the Gastrointestinal Stromal Tumor pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastrointestinal Stromal Tumors (GIST) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Gastrointestinal Stromal Tumor Overview
Gastrointestinal Stromal Tumors (GIST) (GISTs) are among a group of cancers known as sarcomas. GISTs belong to the family of sarcomas, which are malignant tumors that arise from various tissues, including fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels.
Find out more about Gastrointestinal Stromal Tumor Therapeutics Assessment @ Gastrointestinal Stromal Tumor Preclinical and Discovery Stage Products
Gastrointestinal Stromal Tumor Emerging Drugs Profile
- Famitinib: Jiangsu Hengrui Medicine
- Nilotinib: Novartis
- THE-630: Theseus Pharmaceuticals
- DS 6157: Daiichi Sankyo Company
Gastrointestinal Stromal Tumor Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the Gastrointestinal Stromal Tumor therapies. The Gastrointestinal Stromal Tumor companies which have their Gastrointestinal Stromal Tumors drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.
DelveInsight’s Gastrointestinal Stromal Tumor pipeline report covers around 28+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Gastrointestinal Stromal Tumor Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Learn more about the emerging Gastrointestinal Stromal Tumor Pipeline Therapies @ Gastrointestinal Stromal Tumor Clinical Trials Assessment
Scope of the Gastrointestinal Stromal Tumor Pipeline Report
- Coverage- Global
- Gastrointestinal Stromal Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Gastrointestinal Stromal Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Gastrointestinal Stromal Tumor Companies- Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx Inc., Allarity Therapeutics, and others.
- Gastrointestinal Stromal Tumor Pipeline Therapies- DCC-2618, Ripretinib, Sunitinib, DS-6157a, and others.
Dive deep into rich insights for new drugs for Gastrointestinal Stromal Tumor Treatment, Visit @ Gastrointestinal Stromal Tumor Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Gastrointestinal Stromal Tumors: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Gastrointestinal Stromal Tumors – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Famitinib: Jiangsu Hengrui Medicine
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Nilotinib: Novartis
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- DS 6157: Daiichi Sankyo Company
- Drug profiles in the detailed report…..
- Inactive Products
- Gastrointestinal Stromal Tumors Key Companies
- Gastrointestinal Stromal Tumors Key Products
- Gastrointestinal Stromal Tumors- Unmet Needs
- Gastrointestinal Stromal Tumors- Market Drivers and Barriers
- Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion
- Gastrointestinal Stromal Tumors Analyst Views
- Gastrointestinal Stromal Tumors Key Companies
- Appendix
For further information on the Gastrointestinal Stromal Tumor Pipeline therapeutics, reach out to Gastrointestinal Stromal Tumor Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market